MINNEAPOLIS, Nov. 6, 2024
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today
announced it will showcase its market-leading portfolio to advance
cancer research from target discovery to personalized medicine and
cell therapy development at the Society for Immunotherapy of Cancer
(SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Bio-Techne's spatial biology brands, Advanced Cell Diagnostics
(ACD) and Lunaphore, are revolutionizing spatial biology research
with their pioneering innovations that are advancing the
development of tailored immunotherapies to improve patient
outcomes.
At booth #613, ACD will present its wide range of spatial
multiomics products. These products leverage the precise RNAscope™
technology and an advanced protease-free workflow for same-section
RNA and protein detection assays. In combination, these
capabilities empower drug discovery research, accelerate cell and
gene therapy workflows, enable the characterization of key soluble
factors and the immune landscape, and support the development of
improved diagnostic tools for an accelerated path from
translational research to clinical applications.
At booth #701, Lunaphore will showcase its fully-automated,
end-to-end COMET™ suite, designed to provide innovative solutions
in spatial biology for the translational research community. The
complete portfolio will be showcased through product
demonstrations. Furthermore, attendees can test the HORIZON™ image
analysis software, tailored for COMET hyperplex images, offering
new features for intuitive multiomics data and neighborhood
analysis.
"Bio-Techne's spatial biology solutions lead the way in
developing groundbreaking innovations, shaping the future of
scientific discovery," said Dr. Matt
McManus, President of Bio-Techne's Diagnostics & Spatial
Biology Segment. "Our mission is to empower scientists with
cutting-edge technologies to accelerate research and develop the
next-generation therapies. We are excited to feature our
spatial portfolio at this prestigious conference."
Several scientists from the company and its partners will
present posters at the conference highlighting how the
industry-leading capabilities of Bio-Techne's solutions enable key
research and clinical applications.
Bio-Techne poster presentations:
Multiomic mapping of the brain: same-section, fully-automated
spatial RNA and protein detection on mouse frozen
tissues
Friday, November 8 at
12:15 - 13:45 & 17:30 - 19:00
Presenter: Alice Comberlato, Ph.D.,
Lunaphore, a Bio-Techne Brand
Poster number: #81
Novel fully-automated multiomics assay for profiling immune
cell landscape and activation states
Friday, November 8 at 12:15 - 13:45 & 17:30 -
19:00
Presenter: Anushka Dikshit,
Ph.D, Advanced Cell Diagnostics, a Bio-Techne Brand
Poster number: #85
Qualification of immune checkpoint biomarker antibodies in
glioblastoma with multiplex immunofluorescence
Friday, November 8 at 12:15 - 13:45 & 17:30 -
19:00
Presenter: Ruha Adelkar, Bio-Techne
Poster number: #69
High throughput spatial mulitomic assay for assessing immune
cell phenotype and function in the tumor
microenvironment
Saturday, November
9 at 12:15- 13:45 & 19:00 - 20:30
Presenter: Anushka Dikshit, Ph.D.,
Advanced Cell Diagnostics, a Bio-Techne Brand
Poster number: #86
Fully automated, novel protease-free workflow for
co-detection of protein-protein interaction, individual proteins
and mRNA using RNAscope Multiomic LS assay
Saturday, November 9 at 12:15 -13:45 & 19:10
- 20:30
Presenters: Ge-Ah Kim, Advanced Cell
Diagnostics, a Bio-Techne Brand
Poster number: #106
A new automated RNAscopeTM assay for the fluorescent
co-detection of multiple RNA and protein biomarkers on Roche
DISCOVERY ULTRA™
Saturday, November
9 at 12:15- 13:45 & 19:10 - 20:30
Presenters: Renzo Adilardi, Advanced Cell Diagnostics, a Bio-Techne
Brand
Poster number: #206
Poster presentations, in collaboration
Application of a novel multiplex imaging-based immunotherapy
panel and AI-powered analysis solution for spatial biomarker
identification on immunotherapy-treated melanoma patients
[research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute
Fondazione G. Pascale and Nucleai]
Friday, November 8 at 12:15 - 13:45 & 17:30 -
19:00
Presenter: Ettai Markovits, Ph.D., Nucleai
Poster number: #117
Enhanced analysis of tumor microenvironment and immune
regulation via an automated adjustable signal amplification
technique for multiplex immunofluorescence [research
conducted in collaboration with Prof. Janis
Taube, Johns Hopkins University School
of Medicine]
Saturday,
November 9 at13:45 & 19:10 - 20:30
Presenter: François Rivest, Ph.D., Lunaphore, a Bio-Techne
Brand
Poster number: #124
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit https://www.bio-techne.com
or follow the Company on social media at: Facebook, LinkedIn,
Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate
Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting-302296611.html
SOURCE Bio-Techne Corporation
